Cleveland Diagnostics

As conversations at continue to expand how we think about cancer detection, one theme has emerged: while finding more cancer is valuable, we still need increased focus on identifying clinically significant disease.

This article from AUA News highlights the growing concern around overdiagnosis and overtreatment. The IsoPSA Test was designed to address that challenge: improving detection of clinically significant prostate cancer while simultaneously helping reduce unnecessary biopsies and overtreatment of indolent disease.

Read the article here: https://hubs.la/Q04gVrcs0

Live from : There’s still time to visit the team at booth #4111!

Stop by to learn how the IsoPSA Test can support more informed prostate biopsy decisions through more accurate risk stratification.